A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer by Vallis, K, Reilley, R, Scollard, D, Petronis, J, Caldwell, C, Hendler, A, Lockwood, G, Oza, A